New Research Coverage Highlights Lennox International,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
11
New Research Coverage Highlights Lennox International, Momenta Pharmaceuticals, Westlake Chemical Partners LP, Symantec, American Eagle Outfitters, and FTD Companies — Consolidated Revenues, Company Growth, and Expectations for 2019

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Lennox International, Inc. (NYSE: LII ), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ), Westlake Chemical Partners LP (NYSE: WLKP ), Symantec Corporation (NASDAQ: SYMC ), American Eagle Outfitters, Inc. (NYSE: AEO ), and FTD Companies, Inc. (NASDAQ: FTD ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

LII DOWNLOAD: http://MarketSourceResearch.com/register/?so=LII MNTA DOWNLOAD: http://MarketSourceResearch.com/register/?so=MNTA WLKP DOWNLOAD: http://MarketSourceResearch.com/register/?so=WLKP SYMC DOWNLOAD: http://MarketSourceResearch.com/register/?so=SYMC AEO DOWNLOAD: http://MarketSourceResearch.com/register/?so=AEO FTD DOWNLOAD: http://MarketSourceResearch.com/register/?so=FTD

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Lennox International, Inc. (NYSE: LII ), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ), Westlake Chemical Partners LP (NYSE: WLKP ), Symantec Corporation (NASDAQ: SYMC ), American Eagle Outfitters, Inc. (NYSE: AEO ), and FTD Companies, Inc. (NASDAQ: FTD ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 18th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

LENNOX INTERNATIONAL, INC. (LII) REPORT OVERVIEW

Lennox International's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Lennox International reported revenue of $1,030.20MM vs $1,052.30MM (down 2.10%) and analysts estimated basic earnings per share $2.68 vs $2.47 (up 8.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Lennox International reported revenue of $3,839.60MM vs $3,641.60MM (up 5.44%) and analysts estimated basic earnings per share $7.25 vs $6.39 (up 13.46%). Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.68. The estimated EPS forecast for the next fiscal year is $12.35 and is expected to report on February 5th, 2019.

To read the full Lennox International, Inc. (LII) report, download it here: http://MarketSourceResearch.com/register/?so=LII

-----------------------------------------

MOMENTA PHARMACEUTICALS, INC. (MNTA) REPORT OVERVIEW

Momenta Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Momenta Pharmaceuticals reported revenue of $14.88MM vs $24.09MM (down 38.22%) and analysts estimated basic earnings per share -$0.65 vs -$0.44. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Momenta Pharmaceuticals reported revenue of $138.88MM vs $109.62MM (up 26.70%) and analysts estimated basic earnings per share -$1.20 vs -$0.31. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.18. The estimated EPS forecast for the next fiscal year is -$1.53 and is expected to report on February 20th, 2019.

To read the full Momenta Pharmaceuticals, Inc. (MNTA) report, download it here: http://MarketSourceResearch.com/register/?so=MNTA

-----------------------------------------

WESTLAKE CHEMICAL PARTNERS LP (WLKP) REPORT OVERVIEW

Westlake Chemical Partners LP's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Westlake Chemical Partners LP reported revenue of $363.65MM vs $296.78MM (up 22.53%) and analysts estimated basic earnings per share $0.38 vs $0.47 (down 19.15%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Westlake Chemical Partners LP reported revenue of $1,172.98MM vs $986.74MM (up 18.87%) and analysts estimated basic earnings per share $1.71 vs $1.51 (up 13.28%). Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.46. The estimated EPS forecast for the next fiscal year is $1.85 and is expected to report on February 19th, 2019.

To read the full Westlake Chemical Partners LP (WLKP) report, download it here: http://MarketSourceResearch.com/register/?so=WLKP

-----------------------------------------

SYMANTEC CORPORATION (SYMC) REPORT OVERVIEW

Symantec's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Symantec reported revenue of $1,175.00MM vs $1,240.00MM (down 5.24%) and basic earnings per share -$0.01 vs -$0.02. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Symantec reported revenue of $4,834.00MM vs $4,019.00MM (up 20.28%) and analysts estimated basic earnings per share $1.85 vs -$0.17. Analysts expect earnings to be released on January 31st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.38. The estimated EPS forecast for the next fiscal year is $1.18 and is expected to report on May 9th, 2019.

To read the full Symantec Corporation (SYMC) report, download it here: http://MarketSourceResearch.com/register/?so=SYMC

-----------------------------------------

AMERICAN EAGLE OUTFITTERS, INC. (AEO) REPORT OVERVIEW

American Eagle Outfitters' Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, American Eagle Outfitters reported revenue of $1,003.71MM vs $960.43MM (up 4.51%) and analysts estimated basic earnings per share $0.48 vs $0.36 (up 33.33%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, American Eagle Outfitters reported revenue of $3,795.55MM vs $3,609.87MM (up 5.14%) and analysts estimated basic earnings per share $1.15 vs $1.17 (down 1.71%). Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $1.62 and is expected to report on March 14th, 2019.

To read the full American Eagle Outfitters, Inc. (AEO) report, download it here: http://MarketSourceResearch.com/register/?so=AEO

-----------------------------------------

FTD COMPANIES, INC. (FTD) REPORT OVERVIEW

FTD Companies' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, FTD Companies reported revenue of $148.62MM vs $161.30MM (down 7.86%) and analysts estimated basic earnings per share -$1.11 vs -$3.61. For the twelve months ended December 31st, 2017 vs December 31st, 2016, FTD Companies reported revenue of $1,084.03MM vs $1,122.00MM (down 3.38%) and analysts estimated basic earnings per share -$8.52 vs -$3.03. Analysts expect earnings to be released on April 1st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.09. The estimated EPS forecast for the next fiscal year is $0.30 and is expected to report on April 1st, 2019.

To read the full FTD Companies, Inc. (FTD) report, download it here: http://MarketSourceResearch.com/register/?so=FTD

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Hugo Moreau, Media Department Office: +1 (704) 343-6361 E-mail: media@MarketSourceResearch.com

© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 4

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
USFCR Wins 2026 Award for Federal Contracting Services

Updated Category News Views 7

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 3

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 2

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 7

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 28

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 5

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 5

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Crystal Risotti: Leading IT Compliance in Healthcare

Updated Category News Views 6

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSig Technologies Updates on Merger and Share Issuance Plans

Updated Category News Views 169

BioSig Technologies Provides Merger Update LOS ANGELES and VANCOUVER, British Columbia — BioSig Technologies, Inc. (NASDAQ: BSGM), recently provided a significant update regarding its merger with Streamex Exchange Corporation. The recent developments aim to clarify the status of the merger and ensure all shareholders are informed. Details of the Merger Finalization The...

Continue Reading
Al Hurra Cuts Jobs and Merges Iraq Channel Amid Budget Cuts

Updated Category News Views 136

Al Hurra Faces Major Workforce Reductions The parent organization of the Arabic language broadcaster Al Hurra has announced significant layoffs, resulting in the elimination of 160 positions. This decision comes in the wake of a 20% budget cut mandated by the U.S. Congress, as revealed by the company’s CEO in a message to staff. Understanding the Budget Cuts Dr. Jeffrey...

Continue Reading
Strategies for Success in Hinge Research Institute's 2025 Study

Updated Category News Views 627

Innovative Strategies Highlighted in Hinge Research's 2025 Study Hinge Research Institute stands at the forefront of research on professional services growth. With its recent 10th Annual High Growth Study, the institute has delivered crucial insights into how successful firms thrive in today’s rapidly evolving market. The study not only illustrates the growth potential...

Continue Reading
Psyence Biomed Celebrates Milestones in Psilocybin Development

Updated Category News Views 125

Recent Developments in Psyence Biomed's Journey In a significant update shared by Psyence Biomedical Ltd. (Nasdaq: PBM), the company has showcased its achievements, reflecting a positive trajectory in the realm of psychedelic-based therapeutics. Highlights from the update included the impressive valuation of their stake in PsyLabs, strong clinical trial progress, and a...

Continue Reading
Rugby Resources Limited Expands Private Placement Offerings

Updated Category News Views 146

Rugby Resources Limited Expands Private Placement Opportunities Rugby Resources Ltd. (TSX-V: RUG) has announced an important development regarding its private placement offering. Responding to high subscriber demand, the company's board has authorized an increase in the number of available units, raising the offering from 60 million units to an impressive 81.84 million...

Continue Reading